Unlock the Secrets to Success in 2022: A Comprehensive Business Update from Sequana Medical

Sequana Medical NV (Euronext Brussels: SEQUA), a leader in the field of fluid overload treatment for liver disease, heart failure and cancer patients, will reveal its full year financial results for the year ended 31 December 2022 on Thursday, 9 February 2023. With its groundbreaking solutions, the Company is paving the way for better outcomes for those suffering from these life-threatening conditions. Stay tuned to find out how Sequana Medical fared in this critical year.

Join us for a live webcast and conference call at 03:00 pm CET / 09:00 am EST to hear from our management team and get an update on our results for the day. Get ready for a dynamic discussion and all the insights you need to stay informed!

About Sequana Medical

Sequana Medical NV is offering a revolutionary solution to an age-old problem plaguing individuals with liver disease, heart failure and cancer – fluid overload. These patients can suffer from up to 15 liters of extra fluid, leading to increased mortality, severe pain, difficult breathing, restricted mobility and repeated hospitalizations. With limited effective treatment options, Sequana Medical is providing an innovative solution for this “diuretic-resistant” population and improving clinical outcomes, reducing costs and improving their quality of life.

Sequana Medical has developed two proprietary platforms, alfapump® and DSR®, to treat diuretic-resistant fluid overload and provide major clinical and quality of life benefits for patients, while reducing costs for healthcare systems. Their North American POSEIDON study has achieved positive primary endpoint data for alfapump, setting the stage for a Pre-Market Approval (PMA) application filing with the FDA in H2 2023. To further their mission of providing disease-modifying treatments for heart failure, the Company is set to launch the MOJAVE study in Q2 2023, a US multi-centered randomized controlled Phase 1/2a clinical study of DSR 2.0.

Leave a Comment